| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Review |
| Article Title |
Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mihnea-Alexandru Găman, Bahadar Singh Srichawla, Yong-Feng Chen, Poulami Roy, Arkadeep Dhali, Ahmed Nahian, Muhammad Romail Manan, Vincent Kipkorir, Richard Christian Suteja, Lakshmi Venkata Simhachalam Kutikuppala, Amelia Maria Găman and Camelia Cristina Diaconu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Grant Funded by Competitiveness Operational Programme A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT |
149/26.10.2016 (MySMIS2014+: 106774) |
|
| Corresponding Author |
Amelia Maria Găman, Doctor, MD, PhD, Doctor, Doctor, Professor, Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Petru Rareş No. 2, Craiova 200349, Romania. gamanamelia@yahoo.com |
| Key Words |
Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Cardiovascular disease; Hypercholesterolemia; Hypertriglyceridemia; Obesity; Diabetes; Inflammation; Oxidative stress |
| Core Tip |
The topic of dyslipidemia in myeloproliferative neoplasms (MPNs) has only been superficially studied until now. Although it is well known that cardiovascular risk factors impact the management of MPNs and increase the risk of thrombosis which is the main cause of death in MPNs, most investigations have overlooked dyslipidemia as a significant contributor to thrombotic risk and to the risk of death in MPNs. Herein, we provide, to our knowledge, the first overview of lipid abnormalities in MPNs. |
| Publish Date |
2024-06-24 08:56 |
| Citation |
<p>Găman MA, Srichawla BS, Chen YF, Roy P, Dhali A, Nahian A, Manan MR, Kipkorir V, Suteja RC, Simhachalam Kutikuppala LV, Găman AM, Diaconu CC. Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms. <i>World J Clin Oncol</i> 2024; 15(6): 717-729</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i6/717.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i6.717 |
